B+
Bull case
25%
Probability
Target price
$40.00
+146.2% vs current
SRPT
Sarepta TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$24.00
+47.7% vs current
B-
Bear case
25%
Probability
Target price
$12.00
-26.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-12
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Market tone is mixed: analyst consensus leans toward 'Hold' with a wide target spread, reflecting event-driven binary outcomes for Sarepta's programs [#SERP-1]. Recent SEC filings (10-K, 8-K) provide routine disclosure but limited fresh forward guidance, keeping near-term sentiment cautious [#10-K-2026-03-02] [#8-K-2026-02-25].
RankAlpha Sentiment AI - 2026-04-12
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-11catalystNext quarterly report / 10-Q (monitor for guidance and cash/runway commentary)High impact
Market reaction to Sarepta's next quarterly report (Q1 2026 / 10-Q/earnings) could drive share moves; prior cadence and disclosures shown in the 2025 10-Q and 2025 10-K set the baseline for monitoring revenue, royalty disclosures and program updates [#10-Q-2025-11-06] [#10-K-2026-03-02].
2026-12-31catalystPipeline/safety follow-up from recent presentations and program updatesHigh impact
Sarepta indicated presentations of long-term and safety data across gene therapy and exon-skipping programs in its IR materials; further company-updated safety/efficacy follow-ups or regulatory interactions through 2026 would materially re-rate prospects for lead programs [#IR-undated] [#8-K-2026-02-25].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-12 • Updated nightlySource: Internal modelMethodology